Figure 5.

VAY-736 enhances ADCC and NK-cell activation. (A) ⁵¹Cr release assays comparing ADCC mediated by VAY-736 with allogeneic normal donor NK cells and CLL target B cells (P < .001, n = 8 normal donor; n = 7 CLL). (B) Enzyme-linked immunosorbent assay data of IFN-γ release by NK cells incubated with plate-bound VAY-736 vs OBN at 10, 1.0, and 0.1 μg/mL; P < .05, n = 3 NKs, 2 separate experiments. (C-D) Enzyme-linked immunosorbent assay data comparing TNF-α release by monocytes (C) or MDMs (D) stimulated with plate-bound VAY-736, OBN, OFA, RTX, alemtuzumab (ALE), or immunoglobulin G (IgG) (not significant, n = 3). (E) MDMs were labeled with Claret, and CLL B cells were stained with PKH67. ADCP was observed by using flow cytometry and measuring the percentage of cells double-positive for Claret PKH67 (P < .05: untreated vs RTX, vs OBN, vs OFA, vs VAY-736; n = 3). *P < .05 and ***P < .001. TRA, trastuzumab.